Hyper-progressive disease in patients with advanced non-small cell lung cancer (NSCLC) treated with nivolumab (nivo)

被引：0
|
作者：
Costantini, Adrien [1 ]
Corny, Jennifer [2 ]
Fallet, Vincent [1 ]
Renet, Sophie [2 ]
Friard, Sylvie [3 ]
Chouaid, Christos [4 ]
Duchemann, Boris [5 ]
Giroux-Leprieur, Etienne [6 ]
Taillade, Laurent [7 ]
Doucet, Ludovic [8 ]
Nguenang, Marina [9 ]
Jouveshomme, Stephane [10 ]
Wislez, Marie [1 ]
Tredaniel, Jean [10 ]
Cadranel, Jacques [1 ]
机构：
[1] Hop Tenon, Serv Pneumol, Paris, France
[2] Grp Hosp Paris St Joseph, Pharm Clin, Paris, France
[3] Hop Foch, Serv Pneumol, Suresnes, France
[4] Ctr Hosp Intercommunal Creteil, Serv Pneumol, Creteil, France
[5] Hop Avicenne, Serv Oncol Med, Bobigny, France
[6] Hop Ambroise Pare, Serv Pneumol & Oncol, Boulogne Billancourt, France
[7] Hop La Pitie Salpetriere, Serv Oncol Med, Paris, France
[8] Hop St Louis, Serv Oncol Med, Paris, France
[9] Hop Bichat Claude Bernard, Serv Pneumol C, Paris, France
[10] Grp Hosp Paris St Joseph, Serv Pneumol, Paris, France
来源：
EUROPEAN RESPIRATORY JOURNAL | 2018年 / 52卷
关键词：
D O I：
10.1183/13993003.congress-2018.PA2808
中图分类号：
R56 [呼吸系及胸部疾病];
学科分类号：
摘要：
PA2808
引用
收藏
页数：2
相关论文
共 50 条
  • [31] Feasibility Study of Nivolumab and Docetaxel in Previously Treated Patients with Advanced Non-Small Cell Lung Cancer
    Shimokawa, T.
    Nakamura, Y.
    Iwasawa, S.
    Miyazaki, K.
    Yamanaka, T.
    Takiguchi, Y.
    Okamoto, H.
    JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (11) : S2431 - S2431
  • [32] Feasibility study of nivolumab and docetaxel in previously treated patients with advanced non-small cell lung cancer
    Miyazaki, Kazuhito
    Iwasawa, Shunichiro
    Nakamura, Yukiko
    Shimokawa, Tsuneo
    Yamanaka, Takeharu
    Takiguchi, Yuichi
    Okamoto, Hiroaki
    ANNALS OF ONCOLOGY, 2017, 28
  • [33] Nivolumab in Non-Small Cell Lung Cancer (NSCLC): Facing the Reality
    Merimsky, O.
    Shamai, S.
    JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (11) : S2425 - S2425
  • [34] Prolactin as a possible predictive factor in metastatic non-small cell lung cancers (NSCLC) patients in treatment with Nivolumab (NIVO)
    Caponnetto, S.
    Mancini, M. L.
    Scagnoli, S.
    Barchiesi, G.
    Mosillo, C.
    Iannantuono, G. M.
    Verkhovskaia, S.
    Magri, V.
    Piesco, G.
    Pomati, G.
    Pellegrino, D.
    Urbano, F.
    Zancla, S.
    Manai, C.
    Cortesi, E.
    ANNALS OF ONCOLOGY, 2016, 27
  • [35] A retrospective analysis of non-small cell lung cancer patients treated with nivolumab
    Akagi, Kazumasa
    Honda, Noritaka
    Umeyama, Yasuhiro
    Ogawara, Daiki
    Ikeda, Takaya
    Yamaguchi, Hiroyuki
    Kitazaki, Takeshi
    Nakatomi, Katsumi
    Fukuda, Minoru
    Mukae, Hiroshi
    ANNALS OF ONCOLOGY, 2017, 28
  • [36] Immune related adverse events (irAE) and disease response with nivolumab in pre-treated advanced non-small cell lung cancer (NSCLC)
    Connolly, E.
    Mallesara, G.
    Nordman, I.
    ANNALS OF ONCOLOGY, 2017, 28
  • [37] Treatment and relapse of interstitial lung disease in nivolumab-treated patients with non-small cell lung cancer
    Sata, Masafumi
    Sasaki, Shinichi
    Oikado, Katsunori
    Saito, Yoshinobu
    Tominaga, Junya
    Sakai, Fumikazu
    Kato, Terufumi
    Iwasawa, Tae
    Kenmotsu, Hirotsugu
    Kusumoto, Masahiko
    Baba, Tomohisa
    Endo, Masahiro
    Fujiwara, Yutaka
    Sugiura, Hiroaki
    Yanagawa, Noriyo
    Ito, Yoshihiko
    Sakamoto, Takahiko
    Ohe, Yuichiro
    Kuwano, Kazuyoshi
    CANCER SCIENCE, 2021, 112 (04) : 1506 - 1513
  • [38] Phase 3, Randomized Trial (CheckMate 017) of Nivolumab (NIVO) vs Docetaxel in Advanced Squamous (SQ) Cell Non-Small Cell Lung Cancer (NSCLC)
    Reckamp, Karen
    Brahmer, Julie R.
    Spigel, David R.
    Rizvi, Naiyer A.
    Poddubskaya, Elena
    West, Howard
    Eberhardt, Wilfried E. E.
    Baas, Paul
    Antonia, Scott J.
    Pluzanski, Adam
    Vokes, Everett
    Holgado, Esther
    Waterhouse, David
    Ready, Neal
    Gainor, Justin F.
    Aren Frontera, Osvaldo
    Horn, Leora
    Paz-Ares, Luis
    Li, Ang
    Lynch, Mark
    JOURNAL OF THORACIC ONCOLOGY, 2015, 10 (09) : S174 - S175
  • [39] PHASE 3, RANDOMIZED TRIAL (CHECKMATE 017) OF NIVOLUMAB (NIVO) VS DOCETAXEL IN ADVANCED SQUAMOUS (SQ) CELL NON-SMALL CELL LUNG CANCER (NSCLC)
    Rechamp, Karen
    Spigel, David R.
    Rizvi, Naiyer
    Poddubskaya, Elena
    West, Howard
    Eberhardt, Wilfried
    Baas, Paul
    Antonia, Scott J.
    Pluzanski, Adam
    Vokes, Everett E.
    Holgado, Esther
    Waterhouse, David
    Reddy, Neal
    Gainor, Justin
    Frontera, Osvaldo Aren
    Horn, Leora
    Paz-Ares, Luis
    Zhu, Jin
    Lynch, Mark
    Brahmer, Julie
    Asia-Pacific Journal of Clinical Oncology, 2015, 11 : 130 - 130
  • [40] Randomized Results of Fixed-Duration (1 Year) Versus Continuous Nivolumab (nivo) in Patients (pts) with Advanced (adv) Non-Small Cell Lung Cancer (NSCLC)
    Spigel, D. R.
    McCleod, M.
    Hussein, M. A.
    Waterhouse, D. M.
    Einhorn, L.
    Horn, L.
    Creelan, B.
    Babu, S.
    Leighl, N.
    Couture, F.
    Chandler, J.
    Goss, G.
    Keogh, G.
    Garon, E. B.
    Blankstein, K. B.
    Daniel, D. B.
    Mohamed, M.
    Li, A.
    Aanur, N.
    Jotte, R.
    ONCOLOGY RESEARCH AND TREATMENT, 2018, 41 : 108 - 108
12345